2276 (2276) Fair Value & Analysis

Healthcare · Market cap HK$15.6B

2 2276 2276 · HK

PriceHK$32.20

Fair ValueHK$23.77

Upside-26.2%

Quality44/100

Watch 2276 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$14.08 – HK$35.09

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −23.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$31.42 – HK$64.41 · fair‑value band HK$14.08 – HK$35.09 · the HK$32.20 price screens above the HK$23.77 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2276 (2276) currently trades at HK$32.20, while our model-based Fair Value estimate is HK$23.77 — implying the stock looks roughly 26.2% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2276 generated revenue of HK$2.2B at a net margin of 25.5%. Revenue grew 1.6% year over year. It earns a return on equity of 25.8%. The balance sheet holds a net cash position of HK$390M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.2B

Revenue growth (YoY) +1.6%

Net margin 25.5%

Return on equity 25.8%

Free cash flow HK$242M FY2025

P/E ratio 23.2

More key figures

Operating margin 28.2%

EPS (TTM) HK$0.5900

Dividend yield 1.1%

EPS growth (YoY) +16.1%

Net cash HK$390M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2276 reported revenue of HK$2.2B in FY2025 versus HK$1.4B in FY2021, a compound +12.7%/yr. Reported net income was HK$558M in FY2025, compounding +32.0%/yr from FY2021.

Revenue +12.7%/yr

FY21 HK$1.4B

FY22 HK$1.6B

FY23 HK$1.8B

FY24 HK$2.1B

FY25 HK$2.2B

Net income +32.0%/yr

FY21 HK$184M

FY22 HK$249M

FY23 HK$327M

FY24 HK$428M

FY25 HK$558M

Is 2276 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$402.95	$182.39	-55%
EssilorLuxottica Société anonyme ESLOF	$205.86	$114.90	-44%
HOYA Corporation HOCPY	$162.33	$101.00	-38%
Medline Inc MDLN	$33.61	$31.78	-5%
Becton, Dickinson and Company BDX	$147.79	$124.26	-16%
Alcon Inc ALC	$66.11	$36.99	-44%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2276 (2276) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$23.77 versus a price of HK$32.20 — about −26% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2276?

Our model-based fair value for 2276 is HK$23.77 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$32.20.

What is the quality score of 2276?

2276 has a Quality Score of 44/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2276 (2276)?

2276 reported trailing-twelve-month revenue of about HK$2.2B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2276?

The net profit margin of 2276 is about 25.5%, meaning it keeps roughly 25.5% of revenue as net income. Based on the latest reported figures.

Does 2276 pay a dividend?

2276 currently shows a dividend yield of about 1.11% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.